Document:

Addendum No. 1 to the Binding Site Agreement

  
 Exhibit 10.29

 Addendum No. 1 to the Distribution Agreement 

This Addendum No. 1 to the Distribution Agreement (the “Addendum”) is made and entered into as of this 1st day of
February, 2007, by and between diaDexus, Inc. (“DIADEXUS”), and The Binding Site (“BINDING SITE”). 
 WHEREAS, BINDING SITE and DIADEXUS are parties to a Distribution Agreement effective January 30, 2007 (the “Agreement”); 

WHEREAS, the parties desire to amend such Agreement to insert the following language. 

NOW THEREFORE, in consideration of the agreements, mutual representations and covenants contained herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 
 In
Section 3(j) after “such records.” please insert the following language: “BINDING SITE will inform DIADEXUS of any customer complaints related to the Products within 48 hours of becoming aware of the complaint. DIADEXUS will
inform BINDING SITE of complaint information relevant to BINDING SITE services. BINDING SITE will take appropriate corrective action and inform DIADEXUS of action taken. DIADEXUS will process and report any needed Medical Device Reporting (MDR) (per
U.S. 21 CFR Section 803) as appropriate to the FDA. BINDING SITE will assist as needed and requested by DIADEXUS. DIADEXUS will, if the need arises, determine the requirements for and coordinate product recall activities of the Products.
BINDING SITE will assist as needed and requested by DIADEXUS.” 
 IN WITNESS WHEREOF, the parties hereto have caused this
Addendum to be executed by their fully authorized representatives. 
  

											
	BINDING SITE	 		 	DIADEXUS	 	
						
	BY:	 	 /s/ R. Rowland
	 		 	BY:	 	 /s/ Patrick Plewman
	 	
	Printed Name: R. Rowland	 		 	Printed Name: Patrick Plewman	 	
				
	Title: CEO	 		 	Title: President & CEO	 	

											
						
	Date:	 	     2/2/07
	 		 	Date:	 	     2/1/07Addendum No. 2 to the Binding Site Agreement

  
 Exhibit 10.30

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 
 Addendum No. 2 to the Distribution
Agreement 
 This Addendum No. 2 to the Distribution Agreement (the “Addendum”) is made and entered
into as of this 15th day of June, 2007, by and between diaDexus, Inc. (“DIADEXUS”), and The Binding Site (“BINDING SITE”). 
 WHEREAS, BINDING SITE and DIADEXUS are parties to a Distribution Agreement effective January 30, 2007 and modified it with Addendum No. 1 on February 1, 2007 (collectively, the
“Agreement”); 
 WHEREAS, the parties desire to amend such Agreement as follows: 

[*] 
 Please insert the following into
Exhibit A. 
 [*] 
  

							
	 Description
	  	 Unit
	  	Catalog #	  	Lab Price
	 [*] PLAC® Test Kit for Lp-PLA2
	  	 96-well microplate ELISA kit
	  	90106	  	[*]

 BINDING SITE recognizes the importance to
DIADEXUS that BINDING SITE make best efforts to expedite the rate at which customers go live with commercial sales and new customers are enabled. Accordingly both DIADEXUS and BINDING SITE will review this Addendum No. 2 [*] and if
BINDING SITE is making solid commercial efforts to advance Product sales, DIADEXUS will [*]. 
 In addition, all BINDING SITE sales
reporting pursuant to Section 3 (c) provided to DIADEXUS shall be certified for financial accuracy by a financial officer of BINDING SITE. 

  
 IN WITNESS WHEREOF,
the parties hereto have caused this Addendum to be executed by their fully authorized representatives. 
  

									
	BINDING SITE	 	 	 	DIADEXUS
					
	BY:	 	 /s/ R. Rowland
	 		 	BY:	 	 /s/ Patrick Plewman

	Printed Name: R. Rowland	 		 	Printed Name: Patrick Plewman
			
	Title: CEO	 		 	Title: President & CEO
			
	Date: 6/15/07	 		 	Date: 6/19/07Addendum No. 3 to the Binding Site Agreement

  
 Exhibit 10.31

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 
 Addendum No. 3 to the Distribution
Agreement 
 This Addendum No. 3 to the Distribution Agreement (the “3rd Addendum”) is made and entered into as of this 28th day of
October, 2008 (the “3rd Addendum Effective
Date”), by and between diaDexus, Inc. (“DIADEXUS”), and The Binding Site (“BINDING SITE”). 
 WHEREAS, BINDING SITE and DIADEXUS are parties to a Distribution Agreement effective January 30, 2007 and modified it with Addendum No. 1 on February 1, 2007, and Addendum No. 2 on
June 15, 2007 (collectively, the “Agreement”); 
 WHEREAS, the parties desire to amend such Agreement as follows:

  

	1.	Please replace the last sentence of Section 1 (a) with the following language: This Agreement shall [*] unless either party provides notice in writing
30 days prior to [*]. 

  

	2.	Please replace Section 1 (c) Products Covered with the following language: “Products” shall mean those Products listed in Table 1 and Table 2
of Exhibit A, attached. Table 1 and Table 2 may be updated with new Products from time to time. 

  

	3.	Please add the following language to Section 1 (d) Right to Distribute the Products: BINDING SITE may distribute Products listed in Table 1 of Exhibit
A without restriction pursuant to the terms of this Agreement. Only upon the express written consent of DIADEXUS shall BINDING SITE be permitted to [*]. 

 

	4.	Please replace the first sentence of Section 2 (b) with the following language: [*] 

 

	5.	Please replace the first sentence of Section 2 (c) with the following language: Except as provide for in Section 2(d), in order to avoid conflicts of
interest in distribution of DIADEXUS Products, BINDING SITE shall be limited to laboratories [*]. 

  

	6.	[*]. 

  

	7.	Please replace Section 2 (d) with the following language: 

 Customers available to BINDING SITE are those customers defined in this Section 2 (d) and [*] pursuant to Section 2 (k): 

 

	 	(i)	[*] 

	 	(ii)	[*] 

	 	(iii)	[*] 

 [*] shall be only be
made available to BINDING SITE upon the express written consent of DIADEXUS. 
  

	8.	Please remove the following sentence from Section 2 (e): BINDING SITE agrees not to distribute Products to customers for use on [*].

  

	9.	Please replace Section 2(f) with the following language: [*] 

  

	10.	Please add the following new Section 2 (k) to the Agreement: [*]. To facilitate performance under this Agreement with Section 1 (d),
Section 2 (d), and Section 2 (f), DIADEXUS and BINDING SITE shall maintain in good faith, and [*]. For purposes of this Agreement, modification of [*] by DIADEXUS shall fulfill the obligations of written consent under
Section 1 (d) and Section 2 (d). 

  

					
		 	Confidential	 	Page 1 of 3

  

	11.	 Please replace Exhibit A with the Exhibit A attached to this 3rd Addendum. 

ENTIRE AGREEMENT; In the event of any conflict between the terms and conditions of this 3rd Addendum and the Agreement, the terms and conditions of this
3rd Addendum shall control. Except as otherwise provided
in the 3rd Addendum, the parties agree that all provisions
of the Agreement are hereby ratified and agreed to be in full force and effect and are incorporated herein by reference. This 3rd Addendum and the Agreement (as amended hereby), including without limitation all Attachments hereto, contain the
entire agreement among the parties relating to the subject matter herein and all prior proposals, discussions and writings by and among the parties and relating to the subject matter herein, whether written or oral, are superseded hereby and
thereby. None of the terms of this 3rd Addendum shall be
deemed to be amended unless such addendum is in writing, signed by all parties hereto, and recites specifically that it is an addendum to the terms of this 3rd Addendum and Agreement. 
 IN WITNESS WHEREOF, the parties hereto have caused this 3rd Addendum to be executed by their fully authorized representatives. 
  

									
	BINDING SITE	 	 	 	DIADEXUS, INC.
					
	BY:	 	 /s/ R. Rowland
	 		 	BY:	 	 /s/ Patrick Plewman

	Printed Name: R. Rowland	 		 	Printed Name: Patrick Plewman
	Title: CEO	 		 	Title: President & CEO
			
	Date: 10/23/08	 		 	Date: 10/28/08

  

					
		 	Confidential	 	Page 2 of 3

  
 EXHIBIT A

 DIADEXUS LABELED PRODUCTS INCLUDED IN DISTRIBUTOR AGREEMENT: 
 Table 1 lists the Products BINDING SITE may distribute [*]. 
 Table 1. 

 

					
	 Catalog #
	  	 Description
	  	 Unit

	 PLAC® Test ELISA Kit

	90106	  	 Reagent Kit
 ELISA Kit
	  	 1 Coated Microplate
 1 Set
of 6 Calibrators
 1 Conjugate Reagent (23 mL)
 1 Wash Buffer (50 mL)
 1 TMB Substrate (11 mL)

1 Stop Solution 1N HCl (11 mL)

			
	90104	  	 Controls Kit
 for ELISA Kit #90106
	  	 2 Controls:
 • 1 vial
High (3 mL)
 • 1 vial Low (3 mL)

 [*] 
 [*] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	Confidential	 	Page 3 of 3Business Development Addendum to the Distributor Agreement

  
 Exhibit 10.32

  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 Business Development Addendum to the Distributor Agreement

 This Business Development Addendum to the Distributor Agreement (the “BD Addendum”) is made
and entered into as of this 1st day of February 2010 (the
“BD Addendum Effective Date”), by and between diaDexus, Inc. (“DIADEXUS”), and Inova Diagnostics, Inc. (“INOVA”). 
 WHEREAS, INOVA and DIADEXUS are parties to the Distributor Agreement effective January 30, 2007 and modified by Addenda No.1, No.2 and No.3 on February 1, 2007, June 15, 2007 and
October 28, 2008, respectively (collectively, the “Agreement”) by virtue of assignment of the Agreement to INOVA by The Binding Site Inc., under the acquisition agreement dated July 8, 2009 between INOVA and The Binding Site;

 WHEREAS, DIADEXUS has consented to such assignment of the Agreement under the Consent to Assignment effective July 10,
2009 between DIADEXUS, The Binding Site Inc., and INOVA; and 
 WHEREAS, DIADEXUS and INOVA agree to the terms and conditions
and amendments the Agreement as set forth below. 
  

	1.	The terms “BINDING SITE”, “Binding Site” and “TBS” in the Agreement are replaced by “INOVA”. 

 

	2.	By [*] INOVA sales personnel shall complete sales training for Products conducted by DIADEXUS sales managers. 

 

	3.	By [*] INOVA shall provide DIADEXUS a complete and commercially viable 2010 sales plan for Products. 

 

	4.	In [*] INOVA shall qualify, per DIADEXUS provided criteria, existing INOVA customers [*] and shall, upon completion of sales training in Paragraph 2,
[*]. 

  

	5.	Exhibit A of the Agreement is replaced with the Exhibit A attached to this BD Addendum. 

 

	6.	The current [*] is attached hereto. 

  

	7.	[*]. 

  

	8.	[*]. 

  

	9.	[*], INOVA shall only distribute Products listed on Table 1 of Exhibit A. 

 [*] 
  

	10.	The INOVA Product prices set forth in Paragraphs 7 shall be effective until the revenue received by DIADEXUS from INOVA’S sale of Products to [*] under
Paragraph 8 [*]. Upon revenue of Products sold to [*] under Paragraph 8 [*], the Effective INOVA Product Price for Products sold to the [*] shall return to pricing under the Agreement and shall not be subject to
[*]. 

  

	11.	The term of the Agreement shall [*]. DIADEXUS and INOVA shall have formal business reviews [*] to discuss and assess INOVA’S progress [*].

  

	12.	Provided that INOVA meets its obligations set forth above, DIADEXUS shall offer INOVA an extension of the Agreement [*]. 

  

					
		 	Confidential	 	Page 1 of 4

  

	13.	Unless extended by mutual written agreement of the parties, this BD Addendum shall terminate upon [*] (i) written notice from DIADEXUS that INOVA has meet
its obligations set forth above and (ii) [*]. Upon termination of the BD Addendum, Effective INOVA Product Prices shall not be subject to Paragraphs 7, 8 and 9 above. 

ENTIRE AGREEMENT; In the event of any conflict between the terms and conditions of this BD Addendum and the Agreement, the terms and
conditions of this BD Addendum shall control. Except as otherwise provided in the BD Addendum, the parties agree that all provisions of the Agreement are hereby ratified and agreed to be in full force and effect and are incorporated herein by
reference. This BD Addendum and the Agreement (as amended hereby), including without limitation all attachments hereto, contain the entire agreement among the parties relating to the subject matter herein and all prior proposals, discussions and
writings by and among the parties and relating to the subject matter herein, whether written or oral, are superseded hereby and thereby. None of the terms of this BD Addendum shall be deemed to be amended unless such addendum is in writing, signed
by all parties hereto, and recites specifically that it is an addendum to the terms of this BD Addendum and Agreement. 
 IN
WITNESS WHEREOF, the parties hereto have caused this BD Addendum to be executed by their fully authorized representatives. 
  

									
	INOVA DIAGNOSTICS, INC.	 		 	DIADEXUS, INC.
					
	BY:	 	 /s/ Roger Ingles
	 		 	BY:	 	 /s/ Patrick Plewman

	Printed Name: Roger Ingles	 		 	Printed Name: Patrick Plewman
	Title: President & CEO	 		 	Title: President & CEO
			
	Date: March 10, 2010	 		 	Date: March 12, 2010

  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

					
		 	Confidential	 	Page 2 of 4

  
 EXHIBIT A

 DIADEXUS LABELED PRODUCTS INCLUDED IN DISTRIBUTOR AGREEMENT: 
 Table 1 lists the Products INOVA may distribute [*]. 
 Table 1. 

 

							
	 Catalog #
	  	 Description
	  	 Unit
	  	 
	 PLAC® Test ELISA Kit
	  	
	90123	  	 Reagent Kit
 ELISA Kit
	  	 1 Coated Microplate
 1 Set of 6
Calibrators
 1 Set of 2 Controls
 1
Conjugate Reagent (23 mL)
 1 Wash Buffer (50 mL)
 1 TMB Substrate (11 mL)
 1 Stop Solution 1N HCl (11 mL)
	  	

 [*] 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

					
		 	Confidential	 	Page 3 of 4

  
 [*] 

 

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

					
		 	Confidential	 	Page 4 of 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]